Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

1.

Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography.

Harman DJ, Ryder SD, James MW, Jelpke M, Ottey DS, Wilkes EA, Card TR, Aithal GP, Guha IN.

BMJ Open. 2015 May 3;5(4):e007516. doi: 10.1136/bmjopen-2014-007516.

2.

Chronic hepatitis C - what do the new drugs offer and who should get them first?

Ryder SD.

Clin Med. 2015 Apr;15(2):197-200. doi: 10.7861/clinmedicine.15-2-197.

PMID:
25824075
3.

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.

Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM, McHutchison JG, Gane EJ, Foster GR.

J Hepatol. 2015 Mar;62(3):533-40. doi: 10.1016/j.jhep.2014.10.035. Epub 2014 Oct 30.

PMID:
25450717
4.

Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.

Cramp ME, Rosenberg WM, Ryder SD, Blach S, Parkes J.

BMC Gastroenterol. 2014 Aug 7;14:137. doi: 10.1186/1471-230X-14-137.

5.

Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts.

McLernon DJ, Donnan PT, Sullivan FM, Roderick P, Rosenberg WM, Ryder SD, Dillon JF.

BMJ Open. 2014 Jun 2;4(6):e004837. doi: 10.1136/bmjopen-2014-004837.

6.

Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.

Miller MH, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR, Fox R, Hayes PC, Leen C, Millson C, Ryder SD, Tait J, Ustianowski A, Dillon JF; British Viral Hepatitis group; British Society of Gastroenterology Liver Committee; British Association for the Study of Liver; Scottish Society of Gastroenterology; Scottish Viral Hepatitis group; Scottish Viral Hepatitis Nurses group.

Aliment Pharmacol Ther. 2014 Jun;39(12):1363-75. doi: 10.1111/apt.12764. Epub 2014 Apr 22.

PMID:
24754233
7.

Strategies to manage hepatitis C virus (HCV) disease burden.

Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, Nemecek V, Øvrehus AL, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha GE, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, Gower E.

J Viral Hepat. 2014 May;21 Suppl 1:60-89. doi: 10.1111/jvh.12249.

PMID:
24713006
8.

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C.

J Viral Hepat. 2014 May;21 Suppl 1:34-59. doi: 10.1111/jvh.12248.

PMID:
24713005
9.

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ.

J Viral Hepat. 2014 May;21 Suppl 1:5-33. doi: 10.1111/jvh.12247. Review.

PMID:
24713004
10.

Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.

Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Lédinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K.

Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5. doi: 10.1016/j.cgh.2014.01.040. Epub 2014 Feb 12.

PMID:
24530600
11.

The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI).

McLernon DJ, Dillon JF, Sullivan FM, Roderick P, Rosenberg WM, Ryder SD, Donnan PT.

PLoS One. 2012;7(12):e50965. doi: 10.1371/journal.pone.0050965. Epub 2012 Dec 14.

12.

The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call.

Tedder RS, Rodger AJ, Fries L, Ijaz S, Thursz M, Rosenberg W, Naoumov N, Banatvala J, Williams R, Dusheiko G, Chokshi S, Wong T, Rosenberg G, Moreea S, Bassendine M, Jacobs M, Mills PR, Mutimer D, Ryder SD, Bathgate A, Hussaini H, Dillon JF, Wright M, Bird G, Collier J, Anderson M, Johnson AM; Collaborative UK Study of Chronic Hepatitis B Infection (CUSHI-B) Study Group.

Clin Infect Dis. 2013 Apr;56(7):951-60. doi: 10.1093/cid/cis1013. Epub 2012 Dec 7.

13.

The performance of transient elastography compared to clinical acumen and routine tests - what is the incremental diagnostic value?

Dolman GE, Nieboer D, Steyerberg EW, Harris S, Ferguson A, Zaitoun AM, Ryder SD, James MW, Aithal GP, Guha IN.

Liver Int. 2013 Feb;33(2):172-9. doi: 10.1111/liv.12017. Epub 2012 Nov 8.

PMID:
23136951
14.

Economic modelling of early transjugular intrahepatic portosystemic shunt insertion for acute variceal haemorrhage.

Harman DJ, McCorry RB, Jacob RP, Lim TR, O'Neill R, Ryder SD, James MW, Aithal GP, Guha IN.

Eur J Gastroenterol Hepatol. 2013 Feb;25(2):201-7. doi: 10.1097/MEG.0b013e32835a4cb0.

PMID:
23089879
15.

The utility of scoring systems in predicting early and late mortality in alcoholic hepatitis: whose score is it anyway?

Palaniyappan N, Subramanian V, Ramappa V, Ryder SD, Kaye P, Aithal GP.

Int J Hepatol. 2012;2012:624675. doi: 10.1155/2012/624675. Epub 2012 Sep 4.

16.

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.

Tanwar S, Trembling PM, Guha IN, Parkes J, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM.

Hepatology. 2013 Jan;57(1):103-11. doi: 10.1002/hep.26030.

PMID:
22930399
17.

Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis.

Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2012 May;24(5):543-50. doi: 10.1097/MEG.0b013e3283513e69.

PMID:
22337287
18.

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.

Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.

Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x. Epub 2012 Feb 1.

PMID:
22296568
19.

A complex multi-notch astronomical filter to suppress the bright infrared sky.

Bland-Hawthorn J, Ellis SC, Leon-Saval SG, Haynes R, Roth MM, Löhmannsröben HG, Horton AJ, Cuby JG, Birks TA, Lawrence JS, Gillingham P, Ryder SD, Trinh C.

Nat Commun. 2011 Dec 6;2:581. doi: 10.1038/ncomms1584.

PMID:
22146400
20.

A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients.

Lawson A; Trent Hepatitis C Study Group.

J Viral Hepat. 2011 Jul;18(7):e270-7. doi: 10.1111/j.1365-2893.2010.01406.x. Epub 2010 Dec 7.

PMID:
21138506
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk